Main navigation

Products we regulate
Product safety
How we regulate
Guidance and resources
News and Community
About us

Merck Healthcare Pty Ltd

Regulatory activities for this sponsor.

Loading...

Prescription medicine decision summary (1)
ARTG (38) ARTG (38)
Designation or determination (5) Designation or determination (5)
Prescription medicine registration (5)
Cancellation by sponsor (4) Cancellation by sponsor (4)
Australian Public Assessment Report (AusPAR) (1)

2022 (1) 2022 (1)

Search

Filters applied:

Prescription medicine decision summary

Clear all

Sponsor content

1 result(s) found, displaying 1 to 1

Tepmetko

27 January 2022

Prescription medicine decision summary

TGA decision: Tepmetko (tepotinib) is approved to treat locally advanced or metastatic non-small cell lung cancer (NSCLC).

Is there anything wrong with this page?

Help us improve this page

What were you doing? (mandatory)

What went wrong? (mandatory)

Leave this field blank

Using our website

Accessibility
Privacy
Security
Disclaimer
Copyright
Freedom of information

Quick links

Search our databases
Report a problem or side effect
TGA Business Services
Special Access Scheme
Authorised Prescriber
Office of Drug Control - external site
State and territory contacts

Connect with us

Subscribe to updates
Contact us
Facebook - external site
(formerly Twitter) - external site
Youtube - external site
Instagram - external site
LinkedIn - external site

Help us improve

We are always looking for ways to improve our website.

Provide feedback - external site

The Department of Health and Aged Care acknowledges First Nations peoples as the Traditional Owners of Country throughout Australia, and their continuing connection to land, sea and community. We pay our respects to them and their cultures, and to all Elders both past and present.

Merck Healthcare Pty Ltd

Type

Date

Tepmetko

Help us improve this page